{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-053266","form_type":"8-K","ticker":"RFL","cik":"0001713863","company_name":"Rafael Holdings, Inc.","filed_at":"2025-06-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.447227+00:00","generated_at":"2026-05-19T13:37:22.543166+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rafael Holdings Q3 net loss narrows to $4.8M; Phase 3 data expected this month","bullets":["Net loss attributable to Rafael Holdings of $4.8M ($0.19 per share) vs. $32.4M loss ($1.36) in Q3 last year.","Cash and equivalents of $37.9M at April 30, 2025; $25M rights offering closed June 4 with net proceeds of $24.9M.","Cyclo Therapeutics merger completed March 25, 2025; TransportNPC Phase 3 trial fully enrolled for NPC1.","48-week interim analysis results for Trappsol Cyclo expected later this month.","R&D expenses rose to $3.0M and G&A to $3.2M due to Cyclo consolidation."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-053266","json":"https://secwatch.observer/filing/0001213900-25-053266.json","markdown":"https://secwatch.observer/filing/0001213900-25-053266.md","text":"https://secwatch.observer/filing/0001213900-25-053266.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1713863/000121390025053266/0001213900-25-053266-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1713863/000121390025053266/ea0245286-8k_rafael.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T13:37:22.543166+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}